UEG WEEK 2024

The new kids on the block

S1P modulators - dead or alive?

Did we get the pharmacogentics of drugs right?

The battle of IL-23s

A focus on bowel urgency

P19 antagonists - on the way to disease clearence!?

Hot topic deescalation - patients' wish & scientific…

What is early disease? Getting the right drug to the…

Prime time for ultrasound use

Fatigue - still a black box?

JAKies side effects - what is the current place for…

RW data of Ustekinumab and the role of biosimilars

Guselkumab in UC - QUASAR maintenance data

Tamuzimod for long term extension

Mirikizumab is able to induce disease clearance in UC

anti-TL1A in UC

Tofacitinib is effective in UC associated…

Impact of Guselkumab maintenance on histological and…

Tamuzimod per estensione a lungo termine

anti-TL1A nella CU

Guselkumab bei Colitis ulcerosa - die QUASAR…

Risankizumab in CD – expectations vs. reality

Real world data on Risankizumab effectiveness in CD

Guselkumab in patients with Crohn´s disease

Effects of Mirikizumab & Ustekinumab on histological…

Guselkumab nei pazienti con malattia di Crohn

Dati real-world di efficacia di Risankizumab in…

Ryzankizumab w chorobie Crohna – oczekiwania vs.…

How to diagnose PSC associated to IBD

How to diagnose PSC associated to IBD

Evidence based surgery for IBD?

Dosisanpassung bei subkutanem Infliximab

Comment diagnostiquer la CSP associée aux MiCi?

כירורגיה מבוססת ראיות במחלות מעי דלקתיות?

Long-term extension of Mirikizumab - barely any…

Extended induction response in week 12 in non-responder…

Long-term extension of Mirikizumab - significant added…

Live biotherapeutic product for acute pouchitis

Extended induction treatment in active UC can capture…

Induzione prolungata con Mirikizumab in pazienti che…

Long-term Extension von Mirikizumab - deutlicher…

Levend biotherapeutisch medicijn voor acute pouchitis

Παράταση της θεραπείας εφόδου αυξάνει την ανταπόκριση…

Quel traitement après le Vedolizumab dans la RCH?

Data on interaction between biologics and…

Vedolizumab is more effective in early Crohn´s disease

Vedolizumab in early CD

Early treatment with Vedolizumab in patients with CD

Ileocecal resection in CD – GI functional consequences

Zaburzenia czynności przewodu pokarmowego po resekcji…

Efficacité du vedolizumab dans les formes précoces

Interactions entre le traitements biologiques et la…

Früher Einsatz von Vedolizumab bei Patienten mit Morbus…

RXC008 - novel mechanism of action for fibrostenosing…

Tulisokibart - new anti-TL1A agent for treating CD

Divine support for intestinal fibrosis in UC & CD

Topical JAKies - let's try again!

Cellular therapies in IBD – Old and New

Topische JAKies - auf ein Neues!

Tulisokibart - eine neue Therapieoption bei CU

Dezidierte Unterstützung bei intestinaler Fibrose bei…

טיפולים תאיים במחלות מעי דלקתיות-ישן וחדש

Tulisokibart - un nuovo anti-TL1A per il trattamento…

Thiopurines and risk of cancer in IBD

Mirikizumab improves fatigue in patients with CD

Colorectal cancer risk and biologicals in IBD patients

Tiopuryny a ryzyko onkologiczne w IBD

IBS overlapping IBD

VERDICT - Update on week 32 data

Upadacitinib normalizes health-related quality of life…

Το Upadacitinib αποκαθιστά την ποιότητα της ζωής…

IBS overlapping IBD

Biologika haben positiven Effekt auf den Stuhldrang

Whole food diet is more tolerable and equal to…

Focus on nutrition